November 12, 2021 Drug Utilization Review Board (DURB) Agenda
»
Item 1 - Call to order
Item 1
Call to order
»
Item 3 (Part 1 of 2) - Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): (Part 1 of 2)
a. Androgenic agents
b. Antibiotics, gastrointestinal (GI)
c. Antibiotics, topical
d. Antibiotics, vaginal
Item 3 (Part 1 of 2)
Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): (Part 1 of 2)a. Androgenic agents
b. Antibiotics, gastrointestinal (GI)
c. Antibiotics, topical
d. Antibiotics, vaginal
»
Item 2 - Consideration of minutes from July 23, 2021 (vote required)
Item 2
Consideration of minutes from July 23, 2021 (vote required)
»
Item 3 (Part 2 of 2) - Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
e. Anticonvulsants
f. Antiemetics/Antivertigo agents
g. Antifungals, oral
h. Antifungals, topical
i. Antihistamines - first generation
j. Antiparasitics, topical
k. Antipsychotics
l. Antivirals, topical
m. Bone resorption suppression and related agents
n. Colony stimulating factors
o. Epinephrine, self-injected
p. GI Motility, chronic
q. Growth hormone
r. Hepatitis C
s. HIV / AIDS
t. Hypoglycemics, insulin and related agents
u. Hypoglycemics, meglitinides
v. Hypoglycemics, metformin
w. Hypoglycemics, sodium-glucose cotransporter-2 (SGLT2) inhibitors
x. Hypoglycemics, thiazolidinediones (TZDs)
y. Macrolides-Ketolides
z. Opiate dependence treatments
aa. Tetracyclines
Item 3 (Part 2 of 2)
Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): e. Anticonvulsants
f. Antiemetics/Antivertigo agents
g. Antifungals, oral
h. Antifungals, topical
i. Antihistamines - first generation
j. Antiparasitics, topical
k. Antipsychotics
l. Antivirals, topical
m. Bone resorption suppression and related agents
n. Colony stimulating factors
o. Epinephrine, self-injected
p. GI Motility, chronic
q. Growth hormone
r. Hepatitis C
s. HIV / AIDS
t. Hypoglycemics, insulin and related agents
u. Hypoglycemics, meglitinides
v. Hypoglycemics, metformin
w. Hypoglycemics, sodium-glucose cotransporter-2 (SGLT2) inhibitors
x. Hypoglycemics, thiazolidinediones (TZDs)
y. Macrolides-Ketolides
z. Opiate dependence treatments
aa. Tetracyclines
»
Item 4 - Public comment on single new drugs to be reviewed for the Medicaid PDL:
a. Benlysta Autoinjector (subcutane) / Immunosuppressives
b. Benlysta Syringe (subcutane) / Immunosuppressives
c. Lumakras (oral) / Oncology, oral – lung
d. Lupkynis (oral) / Immunosuppressives
e. Truseltiq (oral) / Oncology, oral - other
f. Zegalogue Autoinjector (subcutaneous) / Glucagon agents
g. Zegalogue Syringe (subcutaneous) / Glucagon agents
Item 4
Public comment on single new drugs to be reviewed for the Medicaid PDL:a. Benlysta Autoinjector (subcutane) / Immunosuppressives
b. Benlysta Syringe (subcutane) / Immunosuppressives
c. Lumakras (oral) / Oncology, oral – lung
d. Lupkynis (oral) / Immunosuppressives
e. Truseltiq (oral) / Oncology, oral - other
f. Zegalogue Autoinjector (subcutaneous) / Glucagon agents
g. Zegalogue Syringe (subcutaneous) / Glucagon agents
»
Item 5 - Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
Item 5
Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
»
Item 6 - Executive work session
Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title
1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more
items listed under new business as permitted by the Texas Open Meetings Act.
Item 6
Executive work sessionPursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title
1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more
items listed under new business as permitted by the Texas Open Meetings Act.
»
Item 7 - Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote
required)
Item 7
Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (voterequired)
»
Item 8 (Part 1 of 2) - Retrospective drug utilization review (DUR): Conduent, LLC
a. Recent interventions
i. Caring for patients with dyslipidemia or at risk for coronary heart disease
ii. Influenza prevention: vaccination and education
b. Recent outcome reports
i. Contraceptive drug use evaluation (DUE)
c. Potential retrospective DUR interventions (vote required)
i. Attention-deficit/hyperactivity disorder (ADHD) management
ii. Opioids and central nervous system (CNS) depressants DUE
Item 8 (Part 1 of 2)
Retrospective drug utilization review (DUR): Conduent, LLCa. Recent interventions
i. Caring for patients with dyslipidemia or at risk for coronary heart disease
ii. Influenza prevention: vaccination and education
b. Recent outcome reports
i. Contraceptive drug use evaluation (DUE)
c. Potential retrospective DUR interventions (vote required)
i. Attention-deficit/hyperactivity disorder (ADHD) management
ii. Opioids and central nervous system (CNS) depressants DUE
»
Item 9 - Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required)
a. Topical antifungal for treatment of onychomycosis – new criteria
b. Antipsychotic agents
i. Add Lybalvi - new criteria
c. Cytokine and cell-adhesion molecule (CAM)
i. Add Enspryng – new criteria
d. Lupus – new criteria
i. Benslysta (safety checks)
ii. Lupknis (safety checks)
e. SGLT2
i. Farxiga (revised criteria)
ii. Jardiance (revised criteria)
Item 9
Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required)a. Topical antifungal for treatment of onychomycosis – new criteria
b. Antipsychotic agents
i. Add Lybalvi - new criteria
c. Cytokine and cell-adhesion molecule (CAM)
i. Add Enspryng – new criteria
d. Lupus – new criteria
i. Benslysta (safety checks)
ii. Lupknis (safety checks)
e. SGLT2
i. Farxiga (revised criteria)
ii. Jardiance (revised criteria)
»
Item 10 - Retrospective drug use criteria for outpatient use in Vendor Drug Program:
The University of Texas at Austin College of Pharmacy (vote required)
a. Atypical antipsychotics (long-acting injectable)
b. Atypical antipsychotics (oral)
c. Exogenous insulin products
d. Nitazoxanide (Alinia®)
e. Promethazine use in children less than 2 years of age
f. Quetiapine (low dose)
Item 10
Retrospective drug use criteria for outpatient use in Vendor Drug Program:The University of Texas at Austin College of Pharmacy (vote required)
a. Atypical antipsychotics (long-acting injectable)
b. Atypical antipsychotics (oral)
c. Exogenous insulin products
d. Nitazoxanide (Alinia®)
e. Promethazine use in children less than 2 years of age
f. Quetiapine (low dose)
»
Item 8 (Part 2 of 2) - Retrospective drug utilization review (DUR): Conduent, LLC
a. Recent interventions
i. Caring for patients with dyslipidemia or at risk for coronary heart disease
ii. Influenza prevention: vaccination and education
b. Recent outcome reports
i. Contraceptive drug use evaluation (DUE)
c. Potential retrospective DUR interventions (vote required)
i. Attention-deficit/hyperactivity disorder (ADHD) management
ii. Opioids and central nervous system (CNS) depressants DUE
Item 8 (Part 2 of 2)
Retrospective drug utilization review (DUR): Conduent, LLCa. Recent interventions
i. Caring for patients with dyslipidemia or at risk for coronary heart disease
ii. Influenza prevention: vaccination and education
b. Recent outcome reports
i. Contraceptive drug use evaluation (DUE)
c. Potential retrospective DUR interventions (vote required)
i. Attention-deficit/hyperactivity disorder (ADHD) management
ii. Opioids and central nervous system (CNS) depressants DUE
»
Items 11 & 12 - 11. Review of action and agenda items for next meeting: January 21, 2022
12. Adjournment
Items 11 & 12
11. Review of action and agenda items for next meeting: January 21, 202212. Adjournment
